Kingsoft Cloud Holdings Limited vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kingsoft Cloud Holdings Limited trades at $8.53 (market cap $2.80B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.6× Kingsoft Cloud Holdings Limited's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KC | SYRE | |
|---|---|---|
Market Cap | $2.80B | $7.35B |
Volume | 2,145,784 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $18.21 | $108.92 |
52-Week Low | $8.58 | $22.18 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $3.12B | $6.35B |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.32, up 0.76% with a bearish technical signal despite recent earnings beats. The company shows improving revenue growth with Q2 2026 sales up 30.8% year-over-year and AI cloud services driving 82% growth, though it remains unprofitable with a -5.46% net margin. Analyst sentiment is positive with 70% buy ratings and a consensus price target suggesting 60.3% upside potential.
The stock presents a growth opportunity through AI cloud expansion and margin improvement, but faces execution risks in China's competitive cloud market and persistent profitability challenges. Cash flow volatility and high investing outflows require careful monitoring as the company scales its AI infrastructure investments.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →